Concord Asset Management LLC VA Has $2.85 Million Position in Eli Lilly and Company $LLY

Key Points

• Concord Asset Management LLC increased its holdings in Eli Lilly and Company by 20.2%, owning 3,652 shares worth approximately $2.85 million as of the latest SEC filing.
• Insider transactions include EVP Daniel Skovronsky acquiring 1,000 shares for about $634,400, which reflects a 0.73% increase in his ownership.
• Eli Lilly's stock recently reported earnings of $6.31 per share, exceeding expectations, with forecasted earnings for FY 2025 ranging from $21.75 to $23.00 per share.

Concord Asset Management LLC VA lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 20.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,652 shares of the company's stock after acquiring an additional 614 shares during the period. Concord Asset Management LLC VA's holdings in Eli Lilly and Company were worth $2,847,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC lifted its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Covestor Ltd raised its stake in shares of Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company's stock valued at $352,000 after buying an additional 85 shares during the period. GAMMA Investing LLC increased its holdings in Eli Lilly and Company by 25.8% in the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock worth $14,866,000 after acquiring an additional 3,696 shares during the last quarter. Finally, Warner Financial Inc. boosted its position in Eli Lilly and Company by 129.2% during the first quarter. Warner Financial Inc. now owns 1,123 shares of the company's stock worth $927,000 after purchasing an additional 633 shares during the period. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Daniel Skovronsky acquired 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jamere Jackson bought 200 shares of the company's stock in a transaction on Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Down 1.8%

Shares of NYSE LLY opened at $818.60 on Tuesday. The stock's fifty day simple moving average is $743.43 and its two-hundred day simple moving average is $765.54. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The stock has a market capitalization of $774.77 billion, a PE ratio of 53.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Cantor Fitzgerald set a $925.00 price target on shares of Eli Lilly and Company and gave the stock an "overweight" rating in a report on Thursday. Leerink Partners reissued a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average price target of $948.06.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.